Insulin News and Research RSS Feed - Insulin News and Research

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.
Higher consumption of dietary trans fatty acids may affect memory

Higher consumption of dietary trans fatty acids may affect memory

Higher consumption of dietary trans fatty acids (dTFA), commonly used in processed foods to improve taste, texture and durability, has been linked to worsened memory function in men 45 years old and younger, according to a University of California, San Diego School of Medicine study published online on June 17 in PLOS ONE. [More]
Exploring potential alternatives to needle injections

Exploring potential alternatives to needle injections

Needle injections have been around since 1657 and remain a key delivery method for many drugs, including vaccines that have prevented countless illnesses. But for patients that require daily pricks or for people in remote locations, the syringe model has major drawbacks. An article in Chemical & Engineering News looks at potential alternatives, their successes and their roadblocks. [More]
High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

'Walk through any supermarket and take a look at the labels on food products, and you'll see that many of them contain fructose, often in the form of sucrose (table sugar)' -- that's how Wilhelm Krek, professor for cell biology at ETH Zurich's Institute for Molecular Health Sciences, summarises the problem with today's nutrition. [More]
AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease. [More]
Rare form of autoimmune syndrome may be tied to mutations in AIRE gene

Rare form of autoimmune syndrome may be tied to mutations in AIRE gene

A hereditary autoimmune disease that was thought to be exceedingly rare may have a less severe form that affects one in 1,000 people or even more, according to new research conducted at the Weizmann Institute of Science, in Israel, and the University of Bergen, in Norway. [More]
West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community. [More]
Understanding crosstalk between cells in the pancreas can help treat diabetes

Understanding crosstalk between cells in the pancreas can help treat diabetes

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk is between the cells that control your body's response to sugar, and understanding the conversation can help us understand, and perhaps ultimately treat, diabetes. [More]
Scientists report that mouse with weak bones appears to have strong metabolism

Scientists report that mouse with weak bones appears to have strong metabolism

One mouse with weak bones appears to have a strong metabolism, even on a high-fat diet, scientists report. While weaker bones are clearly not a good thing, scientists suspect that, somewhere in the conversation between the genetically engineered mouse's skeleton and the rest of its body, there may be an answer that helps obese individuals avoid some of the worst ravages of this health epidemic. [More]
Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Nutrinia's NTRA-9620 granted FDA orphan drug designation for treatment of short bowel syndrome

Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company's orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication. [More]
New therapy for osteoporosis may be in the pipeline

New therapy for osteoporosis may be in the pipeline

Researchers from The Scripps Research Institute (TSRI), Florida, have reported a novel therapeutic approach that could promote the formation of new bone cells in people suffering from bone loss. [More]
Study reveals new information about role of abdominal fat in teens with CAH

Study reveals new information about role of abdominal fat in teens with CAH

Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD). [More]
Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes. [More]
Light exercise provides significant health benefits for older adults

Light exercise provides significant health benefits for older adults

An easy walk, slow dancing, leisurely sports such as table tennis, household chores and other light-intensity exercise may be nearly as effective as moderate or vigorous exercise for older adults - if they get enough of that type of activity. [More]
Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

A systematic review publishing today in the journal Human Reproduction Update has found that women who suffer from polycystic ovary syndrome (PCOS) could manage some of the symptoms by combining a change in lifestyle with taking the drug metformin. [More]
Catalan researchers first to use liposomes to fight against diabetes

Catalan researchers first to use liposomes to fight against diabetes

For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work. [More]
Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes. [More]
Researchers pinpoint gene that may solve the root cause of diabetes

Researchers pinpoint gene that may solve the root cause of diabetes

Professor Jeffery Tessem has pinpointed a gene that may help solve a riddle at the root of diabetes, the high-blood-sugar disease affecting 400 million people worldwide. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Advertisement
Advertisement